Laboratoires Servier Acquires Day One Biopharmaceuticals for $2.5B
Analysis based on 9 articles · First reported Mar 06, 2026 · Last updated Mar 06, 2026
The acquisition of Day One Biopharmaceuticals, Inc. by Laboratoires Servier for $2.5 billion is expected to positively impact the pharmaceutical and biotechnology markets, particularly in the oncology sector. It signals continued consolidation and strategic investments in targeted therapies for rare diseases, potentially driving innovation and competition.
Laboratoires Servier, an independent international pharmaceutical group, has entered into a definitive agreement to acquire Day One Biopharmaceuticals, Inc. for $21.50 per share in cash, totaling approximately $2.5 billion. This acquisition, expected to close in the second quarter of 2026, will significantly strengthen Laboratoires Servier's position in oncology targeted therapies, especially in pediatric low-grade glioma. It expands Laboratoires Servier's oncology pipeline with programs ranging from early stage to phase 3, aligning with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. Day One Biopharmaceuticals, Inc.'s scientific expertise combined with Laboratoires Servier's global capabilities is anticipated to accelerate the delivery of innovative solutions for patients worldwide. Olivier Laureau, President of Laboratoires Servier, and Tarkus, CEO of Day One Biopharmaceuticals, Inc., both expressed positive outlooks on the strategic benefits of this merger.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard